Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis.
Curr Rheumatol Rep
; 26(1): 12-23, 2024 Jan.
Article
en En
| MEDLINE
| ID: mdl-38015334
PURPOSE OF REVIEW: Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a rare, multisystem, autoimmune disease characterised by microvascular inflammation. Over the past 20 years, advances in immunological management have improved short-term patient outcomes. Longer-term patient outcomes remain poor with cardiovascular disease now the leading cause of death in AAV. Here, we examine the potential pathways that contribute to the increased risk of cardiovascular disease in AAV and the current evidence to manage this risk. RECENT FINDINGS: The incidence of cardiovascular disease in AAV exceeds that expected by traditional risk factors alone, suggesting a contribution from disease-specific factors. Similarly, it is unclear how different immunosuppressive therapies contribute to and modify cardiovascular risk, and there is a paucity of data examining the efficacy of traditional cardioprotective medications in AAV. There is a lack of evidence-based cardiovascular risk assessment tools and cardioprotective therapies in patients with AAV which should be addressed to improve long-term outcomes.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Cardiovasculares
/
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos
Límite:
Humans
Idioma:
En
Revista:
Curr Rheumatol Rep
Asunto de la revista:
REUMATOLOGIA
Año:
2024
Tipo del documento:
Article